Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 23, 20 December 2023
Open
Access | Article
Combination of radiotherapy and immunotherapy for drug-resistant TNBC
* Author to whom correspondence should be addressed.
Abstract
Triple-negative breast cancer (TNBC) is a specific subtype, the most lethal and with the worst prognosis, and is prone to develop drug resistance during advanced chemotherapy. The combined application of radiotherapy and immunotherapy has gradually entered the public eye. The PD-L1 / PD-1 immune checkpoint inhibitors can enhance the local effect of radiotherapy and relieve the immunosuppressive effect in tumor patients, and the up-regulation of PD-L1 expression caused by radiotherapy also helps the checkpoint inhibitors to play a stronger effect. More patients with TNBC can gain a higher benefit from this.
Keywords
TNBC, immunotherapy, radiotherapy
References
1. Dent R, Trudeau M，Pritchard KI，et al. Triple-negative breast cancer: clinical features and patterns of recurrence [J] . Clin Cancer Res2007，13( 15 Pt 1) : 4429-4434
2. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. NCCN Guidelines Insights: Breast Cancer, Version 1. 2017. J Natl Compr Canc Netw. 2017;15:433–451. [PubMed: 28404755]
3. Nedeljković M, Damjanović A. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells. 2019 Aug 22;8(9):957. doi: 10. 3390/cells8090957. PMID: 31443516; PMCID: PMC6770896.
4. Xu Yunyun, Hong Mei, Li Guixiang. Effect of radiotherapy on the mechanism of anti-tumor immune effects in the body [J]. Modern Oncology, 2016, 24 (24): 4023-4025.
5. Emens LA. Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res. 2018 Feb 1;24(3):511-520. doi: 10. 1158/1078-0432. CCR-16-3001. Epub 2017 Aug 11. PMID: 28801472; PMCID: PMC5796849.
6. Wang Qin. Changes of immune cells and their curative effects of radiotherapy combined or non-com-joined immunotherapy for different tumors [D]. Southern Medical University, 2022. DOI:10. 27003/d. cnki. gojyu. 2022. 000321.
7. Dovedi SJ, Lipowska-Bhalla GL, Beers SA，et al．Anti-tumor efficacy of radiation and immunotherapy combinations is dependent on dendritic cell activation of effector CD8 + T-cells [J]. Cancer Immunol Res, 2016, 4( 7) : 621-630．
8. Zhang B, Bowerman NA, Salama JK, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells [J]. J Exp Med, 2007, 204(1) :49-55.
9. Liu Chao, Wu Shikai. Research progress on the anti-tumor immune mechanism of radiotherapy combined immunotherapy [J]. Military Medicine, 2016, 40 (04): 353-355+359.
10. Burnette B, Weichselbaum RR. The immunology of ablative radiation [J]. Semin Radiat Oncol, 2015, 25(1) : 40-45.
11. Persa E, Balogh A, Safrany G, et al. The effect of ionizing radiation on regulatory T cells in health and disease [J] . Cancer Lett, 2015, 368(2):252-261.
12. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice [J]. J Clin Invest, 2014, 124(2):687-695．
13. Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015 Sep 10;162(6):1229-41. doi: 10. 1016/j. cell. 2015. 08. 016. Epub 2015 Aug 27. PMID: 26321679; PMCID: PMC4864363.
14. Mediratta K, El-Sahli S, D'Costa V, et al. Current progresses and challenges of immunotherapy in triple-negative breast cancer [J]. Cancers (Basel), 2020, 12(12):E3529.
15. Li Chenyang, Liu Qiufang, Wang Tianchang, etc. Research progress on advanced breast cancer radiotherapy combined with PD-1/PD-L1 inhibitor treatment [J]. Chinese Journal of Tumor Prevention and Control, 2023, 30(07):436-442. DOI:10. 16073/j. cnki. cjcpt. 2023. 07. 10.
16. Ho AY, Barker CA, Arnold BB, Powell SN, Hu ZI, Gucalp A, Lebron-Zapata L, Wen HY, Kallman C, D'Agnolo A, Zhang Z, Flynn J, Dunn SA, McArthur HL. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer. 2020 Feb 15;126(4):850-860. doi: 10. 1002/cncr. 32599. Epub 2019 Nov 20. PMID: 31747077.
17. Niesel K, Schulz M, Anthes J, Alekseeva T, Macas J, Salamero-Boix A, Möckl A, Oberwahrenbrock T, Lolies M, Stein S, Plate KH, Reiss Y, Rödel F, Sevenich L. The immune suppressive microenvironment affects efficacy of radio-immunotherapy in brain metastasis. EMBO Mol Med. 2021 May 7;13(5):e13412. doi: 10. 15252/emmm. 202013412. Epub 2021 Mar 23. PMID: 33755340; PMCID: PMC8103101.
18. Kim H, Chung JH. PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future [J]. J Pathol Transl Med. 2019, 53(4): 199-206. doi: 10. 4132/jptm. 2019. 04. 24.
19. Omori S, Kenmotsu H, Abe M, et al. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments [J]. Int J Clin Oncol. 2018, 23(6): 1052-1059. doi: 10. 1007/s10147-018-1305-4
20. Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies [J]. Ann Oncol. 2016, 27(1): 147-153. doi: 10. 1093/annonc/mdv489.
21. Kim S, Koh J, Kwon D, et al. Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas [J]. Eur J Cancer. 2017, 75: 141-149. doi: 10. 1016/ j. ejca. 2017. 01. 004.
22. Herbst RS, Baas P, Perez-Gracia JL, et al. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial [J]. Ann Oncol. 2019, 30(2): 281-289. doi: 10. 1093/annonc/mdy545.
23. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer [J]. Ann Oncol. 2016, 27(3): 409-416. doi: 10. 1093/annonc/mdv615.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-219-0
- ISBN (Online)
- 978-1-83558-220-6
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/23/20231023
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited